131 related articles for article (PubMed ID: 38491962)
21. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
Poulos C; Kinter E; van Beek J; Christensen K; Posner J
Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
[TBL] [Abstract][Full Text] [Related]
22. Patient Preferences for Chronic Myeloid Leukemia Medication Regimen Attributes and their Potential Impact on Adherence: Results from a Multi-national Conjoint Study.
Hirji I; Grinspan J; Flood E; Chirovsky D; Devlen J; Wagner S; Davis C
J Health Econ Outcomes Res; 2014; 2(1):75-86. PubMed ID: 37664084
[No Abstract] [Full Text] [Related]
23. Patients' preferences for the treatment of anxiety and depressive disorders: a systematic review of discrete choice experiments.
Tünneßen M; Hiligsmann M; Stock S; Vennedey V
J Med Econ; 2020 Jun; 23(6):546-556. PubMed ID: 32011209
[No Abstract] [Full Text] [Related]
24. Assessing the impact of excluded attributes on choice in a discrete choice experiment using a follow-up question.
Mansfield C; Sutphin J; Boeri M
Health Econ; 2020 Oct; 29(10):1307-1315. PubMed ID: 32627284
[TBL] [Abstract][Full Text] [Related]
25. Ranking of meal preferences and interactions with demographic characteristics: a discrete choice experiment in young adults.
Livingstone KM; Lamb KE; Abbott G; Worsley T; McNaughton SA
Int J Behav Nutr Phys Act; 2020 Dec; 17(1):157. PubMed ID: 33261647
[TBL] [Abstract][Full Text] [Related]
26. Women's preferences for attributes of first-trimester miscarriage management: a stated preference discrete-choice experiment.
Petrou S; McIntosh E
Value Health; 2009 Jun; 12(4):551-9. PubMed ID: 18798807
[TBL] [Abstract][Full Text] [Related]
27. A discrete-choice experiment to assess treatment modality preferences of patients with depression.
Lokkerbol J; Geomini A; van Voorthuijsen J; van Straten A; Tiemens B; Smit F; Risseeuw A; Hiligsmann M
J Med Econ; 2019 Feb; 22(2):178-186. PubMed ID: 30501437
[TBL] [Abstract][Full Text] [Related]
28. A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients in Japan.
Komine M; Kim H; Yi J; Zhong Y; Sakai Y; Crawford B; Habiro K; Hikichi Y; Feldman SR
J Dermatol; 2023 Jun; 50(6):766-777. PubMed ID: 36808765
[TBL] [Abstract][Full Text] [Related]
29. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
30. Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives.
Peña-Quintana L; Llarena M; Reyes-Suárez D; Aldámiz-Echevarria L
Patient Prefer Adherence; 2017; 11():1489-1496. PubMed ID: 28919721
[TBL] [Abstract][Full Text] [Related]
31. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment.
Boeri M; Sutphin J; Hauber B; Cappelleri JC; Romero W; Di Bonaventura M
J Dermatolog Treat; 2022 May; 33(3):1449-1458. PubMed ID: 33023361
[TBL] [Abstract][Full Text] [Related]
32. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers.
Morel T; Aymé S; Cassiman D; Simoens S; Morgan M; Vandebroek M
Orphanet J Rare Dis; 2016 May; 11(1):70. PubMed ID: 27225337
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Naïve Patients with Type 2 Diabetes Mellitus: A Multinational Preference Study.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):321-334. PubMed ID: 28155131
[TBL] [Abstract][Full Text] [Related]
34. Chinese patients' preference for pharmaceutical treatments of osteoporosis: a discrete choice experiment.
Si L; Tu L; Xie Y; Palmer AJ; Gu Y; Zheng X; Li J; Lv Q; Qi J; Lin Z; Chen M; Gu J; Hiligsmann M
Arch Osteoporos; 2019 Jul; 14(1):85. PubMed ID: 31367860
[TBL] [Abstract][Full Text] [Related]
35. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
[TBL] [Abstract][Full Text] [Related]
36. A stated preference survey to explore patient preferences for novel preventive migraine treatments.
Hubig LT; Smith T; Chua GN; Lloyd AJ; Powell L; Johnston K; Harris L; L'Italien G; Coric V; Lo SH
Headache; 2022 Oct; 62(9):1187-1197. PubMed ID: 36047857
[TBL] [Abstract][Full Text] [Related]
37. Glucagon-Like Peptide-1 Receptor Agonist Treatment Attributes Important to Injection-Experienced Patients with Type 2 Diabetes Mellitus: A Preference Study in Germany and the United Kingdom.
Qin L; Chen S; Flood E; Shaunik A; Romero B; de la Cruz M; Alvarez C; Grandy S
Diabetes Ther; 2017 Apr; 8(2):335-353. PubMed ID: 28236271
[TBL] [Abstract][Full Text] [Related]
38. Randomized, open-label preference study of two cyclosporine capsule formulations (usp modified) in stable solid-organ transplant recipients.
Steinberg SM; Venuto RC; Kuruvila CK; Taylor DO; Anil Kumar MS; Groothuis JR; Ryan J; Greco R; Yeldandi V; Ashraf T; Boodhoo T;
Clin Ther; 2003 Jul; 25(7):2037-52. PubMed ID: 12946549
[TBL] [Abstract][Full Text] [Related]
39. Social preference weights for treatments in Fabry disease in the UK: a discrete choice experiment.
Lloyd AJ; Gallop K; Ali S; Hughes D; MacCulloch A
Curr Med Res Opin; 2017 Jan; 33(1):23-29. PubMed ID: 27590169
[TBL] [Abstract][Full Text] [Related]
40. Patient preferences for osteoporosis in Spain: a discrete choice experiment.
Darbà J; Restovic G; Kaskens L; Balbona MA; Carbonell A; Cavero P; Jordana M; Prieto C; Molina A; Padró I
Osteoporos Int; 2011 Jun; 22(6):1947-54. PubMed ID: 20838770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
